Shukra Pharmaceuticals
Shukra Pharmaceuticals (SHUKRAPHAR) share price was ₹71.92 at the 28 Oct 2026 close; market capitalisation ₹3,162 Cr; P/E (TTM) 88.79; sector Healthcare. The share price rose 71.7% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹24 Cr, against ₹5 Cr a year earlier and net profit was ₹15 Cr, against ₹1 Cr a year earlier (compared with Jun 2025). Promoters held 51.15% of Shukra Pharmaceuticals in Sep 2026, up 0.19 percentage points from Jun 2026. Its Tapetide Score is 61/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 15:59 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,757.50 | 34.86 | 4,21,683 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,558.50 | 86.75 | 2,53,748 Cr | 15.14 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,557.00 | 71.54 | 1,73,334 Cr | 9.43 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,181.90 | 107.80 | 1,17,891 Cr | 22.24 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,175.50 | 26.16 | 1,17,257 Cr | 4.33 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,335.40 | 34.59 | 1,11,463 Cr | 2.87 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.60 | 32.72 | 1,10,321 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Shukra Pharmaceuticals (this company) | ₹71.92 | 88.79 | 3,162 Cr | 31.54 | 0.01% | 24.54% | 31.66% | 79 Cr | 35 Cr |
| Median 8 companies | ₹1,561.55 | 53.20 | 1,17,574 Cr | 7.24 | 0.47% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100. How it works →
v2.0.0
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 175% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%
Weaknesses
2- Stock is trading at 34.4 times its book value
- Debtor days have increased from 122 to 148 days.
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 90% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 20 | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 |
| Operating Profit | 0 | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | 0 | 27 | 1 | 21 |
| OPM % | 1.7% | 21% | 51% | 41% | 25% | 12% | 37% | 55% | 24% | -7% | 69% | 11% | 90% |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 0 | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 |
| Tax % | 2% | 0% | 1% | 24% | 41% | 39% | 23% | 29% | 26% | -1090% | 24% | 568% | 26% |
| Net Profit | 0 | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 15 |
| EPS (₹) | 0.01 | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.34 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 75 | 33 | 57 | 75 |
| Expenses | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 55 | 20 | 28 | 26 |
| Operating Profit | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 | 13 | 29 | 49 |
| OPM % | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 26% | 39% | 51% | 65% |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 |
| PBT | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 29 | 48 |
| Tax % | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | 7% | 28% | 23% | — |
| Net Profit | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | 10 | 22 | 36 |
| EPS (₹) | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0.02 | 0.1 | 0.42 | 0.22 | 0.5 | 0.81 |
| Div. Payout % | 0% | 0% | 16% | 15% | 17% | 0% | 0% | 10% | 4% | 6% | 5% | 2% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 | 44 |
| Reserves | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 | 46 |
| Borrowings | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 3 | 4 | 5 |
| Other Liabilities | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 17 | 20 | 23 |
| Total Liabilities | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
| Fixed Assets | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 | 22 |
| CWIP | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 56 | 65 | 84 |
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 | 117 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -2 | 3 | 0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 | 3 |
| Investing | 1 | 0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | -1 | -1 | -14 |
| Financing | 1 | -1 | 0 | 3 | 2 | 2 | 2 | -7 | 5 | 12 | -5 | 5 |
| Net Cash Flow | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 2 | -6 |
| Free Cash Flow | -1 | 2 | -1 | -4 | -2 | -2 | -1 | 6 | -1 | -7 | 5 | -13 |
| CFO/OP | 812 | 237 | 7 | 63 | 25 | 81 | 38 | 292 | 64 | -24 | 92 | 17 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 | 120 | 98 | 148 |
| Inventory Days | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 | 19 | 447 | 320 |
| Days Payable | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 271 | 59 | 414 | 232 |
| Cash Conversion Cycle | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -58 | 80 | 131 | 236 |
| Working Capital Days | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 57 | 41 | 157 | 403 | 352 |
| ROCE % | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% | 44% | 22% | 37% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Shukra Pharmaceuticals insights
62 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Shukra Pharmaceuticals
What does Shukra Pharmaceuticals Ltd do?
Where is Shukra Pharmaceuticals Ltd (SHUKRAPHAR) listed?
Which sector does Shukra Pharmaceuticals Ltd belong to?
What is the market capitalisation of Shukra Pharmaceuticals Ltd?
What is the PE ratio of Shukra Pharmaceuticals Ltd?
What is the 52-week high and low of Shukra Pharmaceuticals Ltd?
Does Shukra Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Shukra Pharmaceuticals Ltd?
Company Information
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524632.md for Shukra Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.